Management of Patients on Apixaban Requiring Incision and Drainage

Preprocedural Assessment and Preparation

A complete blood count (CBC) should be ordered to assess baseline hemoglobin, hematocrit, and platelet count in patients on apixaban requiring incision and drainage (I&D) procedures 1
Renal function tests, including creatinine and calculation of creatinine clearance (CrCl) using the Cockcroft-Gault formula, should be performed to determine the appropriate timing of apixaban discontinuation, as recommended by the American Society of Anesthesiologists 2, 3
A coagulation profile, including PT/INR, should be obtained, although specific apixaban levels are not routinely needed, according to the American College of Cardiology 4, 2

For patients on a twice daily regimen of apixaban, the last dose should be taken on the morning of the day before the I&D procedure, as recommended by the American Heart Association 1, 4
For patients with renal impairment (CrCl 30-50 mL/min), longer discontinuation periods should be considered, according to the National Kidney Foundation 2, 3

Preoperative bridging with heparin (UFH or LMWH) is generally not recommended for patients on apixaban, as stated by the American College of Chest Physicians 4, 2
Routine biological monitoring of apixaban levels before the procedure is not necessary, according to the International Society on Thrombosis and Haemostasis 4, 2

For low bleeding risk procedures with adequate hemostasis, apixaban can be resumed at least 6 hours after the end of the procedure, as recommended by the European Society of Cardiology 1, 4
For patients with ongoing bleeding or surgical contraindication, resumption of apixaban should be delayed and venous thromboprophylaxis considered, according to the American College of Surgeons 1, 3

For patients with higher bleeding risk or incomplete hemostasis, therapeutic anticoagulation should be delayed for 24-72 hours postoperatively, as recommended by the Society of Critical Care Medicine 2, 3
Creatinine clearance should be monitored postoperatively if the procedure or patient's condition could affect renal function, according to the National Institute of Diabetes and Digestive and Kidney Diseases 3, 6

Failing to assess renal function before determining the appropriate discontinuation period can increase the risk of bleeding complications, as warned by the American Society of Nephrology 2, 3
Unnecessary bridging with heparin products can increase bleeding risk without reducing thrombotic risk, as cautioned by the American College of Cardiology 4, 2
Resuming full-dose anticoagulation too early in cases with incomplete hemostasis can lead to bleeding complications, as advised by the European Society of Cardiology 1, 3